The New York Entrepreneur

Wave Life Sciences’ stock soars 51% after biotech posts positive data from Duchenne muscular-dystrophy trial

Read Time:6 Second

Biotech reported positive interim data from a mid-stage trial of a treatment for the rare muscle disorder Duchenne muscular dystrophy.

About Post Author

Happy
Happy
0 %
Sad
Sad
0 %
Excited
Excited
0 %
Sleepy
Sleepy
0 %
Angry
Angry
0 %
Surprise
Surprise
0 %

Average Rating

5 Star
0%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%

Leave a Reply

Your email address will not be published. Required fields are marked *

Previous post As Visa’s stock drops, here’s why a possible antitrust case could be so worrying
Next post Buy this REIT’s stock to make money on the rapid aging of America’s population